Target intelligence / Profile preview

Novel transcript, antisense to AVL9 (ENSG00000293957)

Target
ENSG00000293957
Molecular classification
Other (Antisense long non-coding RNA)
01

Overview

This transcript is a long non-coding RNA (lncRNA) that is produced from the antisense strand of the *AVL9* locus (chromosome 7), designated ENSG00000293957. Antisense lncRNAs can modulate the expression of their sense protein-coding counterparts by affecting chromatin architecture, RNA stability, or transcript processing[2][4]. In humans and yeast, widespread antisense transcription can alter chromatin marks and gene expression dynamics near the promoter of the sense gene. For this transcript, such activity may theoretically influence the production, processing, and stability of *AVL9* mRNA and thereby indirectly affect cell migration or related biological processes governed by *AVL9*[3][4]. However, the clinical and functional significance of ENSG00000293957 remains uncharacterized, and it is not a therapeutic target nor recognized in structured drug-disease pathways.\nThere is no evidence of interaction with approved drugs, disease-modifying roles, or use as a biomarker. The entry likely represents a non-coding genomic feature without direct translational application.

Other names
Antisense RNA to AVL9antisense lncRNA ENSG00000293957
02

Mechanism of action

Modulation of *AVL9* sense mRNA transcription via chromatin environment changes\nHistone acetylation modification affecting expression and transcript stability[2][4]

03

Biological functions

Regulation of sense *AVL9* gene transcriptionEpigenetic modulation (chromatin remodeling associated with antisense transcription)

Beyond the preview

Go deeper on Novel transcript, antisense to AVL9 (ENSG00000293957).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novel transcript, antisense to AVL9 (ENSG00000293957).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call